Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06128629 | MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) | PHASE3 | RECRUITING | 1,200 | — | — | Dec 13, 2023 | Apr 1, 2028 | Mar 27, 2026 | 132 | United States, Argentina +24 |
| Arm | Type | Description |
|---|---|---|
| NTLA-2001 | EXPERIMENTAL | Single intravenous (IV) infusion of NTLA-2001 |
| Placebo | PLACEBO_COMPARATOR | Single IV infusion of normal saline |
| Name | Type | Description |
|---|---|---|
| NTLA-2001 | BIOLOGICAL | NTLA-2001 (55mg) by IV infusion |
| Placebo | DRUG | Normal saline (0.9% NaCl) by IV infusion |
Inclusion Criteria: * Documented diagnosis of ATTR amyloidosis with cardiomyopathy * Medical history of heart failure (HF) * Symptoms of HF are optimally managed and clinically stable within 28 days prior to administration of study intervention * Screening NT-proBNP, a blood marker of HF severity, ...